
Exercise PVR: A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Sanjiv J. Shah, MD

Stone Professor of Medicine
Director of Research, Bluhm Cardiovascular Institute
Division of Cardiology, Department of Medicine
Director, Center for Deep Phenotyping and Precision Therapeutics,
Institute for Augmented Intelligence in Medicine
Northwestern University Feinberg School of Medicine
sanjiv.shah@northwestern.edu • http://www.hfpef.org • Twitter: @HFpEF

Pre-specified subgroup analyses



Responder analysis

$PA pressure = PVR \times CO + PCWP$

- Markers of pulmonary vascular disease
 - ✓ PVR at rest, peak
 - ✓ PASP at rest, legs up, 20W, peak
 - ✓ TPR (mPAP/CO) at rest, peak
 - ✓ PA compliance at rest/peak
 - ✓ PASP/SV at rest, peak
- Hemodynamic markers of RV dysfunction
 - ✓ PCWP-CVP at rest, legs up, 20W, peak
 - ✓ TAPSE/PASP ratio










- Time to first HF event
- Total (first and recurrent) HF events
- Change in KCCQ, baseline to 12 months


What is a normal peak exercise PVR?




- Study of 55 healthy participants
- Right heart catheterization
- Mean age 50, 36% age >55
- Similar resting hemodynamics in both age groups (<55 and >55 yrs)
- Older healthy individuals have ↑PA pressure and ↑PCWP, ↓CI during exercise
- Mean peak PVR = 1.0, SD = 0.4 WU
- Peak exercise PVR upper limit of normal (mean+2SD): 1.8 WU

Latent PVD: worse outcomes with IASD


Latent PVD = peak exercise PVR ≥1.74 WU (highest tertile)



Resting vs. exercise PVR in REDUCE II




Peak exercise PVR vs. delta PCWP, RAP




RA pressure






Effect of shunt on KCCQ by peak exercise PVR



Borlaug BA…Shah SJ. *Circulation* 2022

Effect of shunt on KCCQ by ± latent PVD



Borlaug BA...Shah SJ. Circulation 2022

Effect of shunt on echo by ± latent PVD

No latent PVD (peak exercise PVR <1.74 WU)

Echo change variable (baseline to 12 months)	Shunt device	Sham control	P-value
RA volume	↑	\leftrightarrow	<0.001
RV end-diastolic volume	↑	\leftrightarrow	<0.001
TAPSE	\leftrightarrow	\leftrightarrow	0.25
TR severity	↑	\leftrightarrow	<0.001
LA volume	\leftrightarrow	\leftrightarrow	0.90
LV end-diastolic volume	\leftrightarrow	\leftrightarrow	0.16
LVEF	\leftrightarrow	\leftrightarrow	0.97


Effect of shunt on echo by ± latent PVD

Latent PVD (peak exercise PVR ≥1.74 WU)


Echo change variable (baseline to 12 months)	Shunt device	Sham control	P-value
RA volume	↑	↑	0.227
RV end-diastolic volume	↑	↑	0.367
TAPSE	\leftrightarrow	\leftrightarrow	0.366
TR severity	↑	↑	0.956
LA volume	\leftrightarrow	\leftrightarrow	0.383
LV end-diastolic volume	\	\leftrightarrow	0.008
LVEF	\leftrightarrow	\leftrightarrow	0.481

Responder analysis

Latent PVD = peak exercise PVR ≥1.74 WU



Overall efficacy of shunt by peak exercise PVR



- ~50% of patients had exercise PVR <1.74 and no pacemaker
- These patients had more "wins" when treated with atrial shunt device (↓HF hospitalizations and ↑health status)
- Opposite was true in those with exercise PVR ≥1.74 or pacemaker

Future directions: 1 Precision medicine



Definite HFpEF (exercise PCWP ≥25 mmHg)

Excluding RV dysfunction, ≥2+ TR, resting PVR >3.5 WU

Excluding PVD during exercise and PM

*PVD = pulmonary vascular disease, defined as abnormal ↑PVR during exercise (~1.8 WU or higher) PM = pacemaker

Most major pharma trials

REDUCE LAP-HF II trial

Large potential responder group for future trials of interatrial shunt devices (~50% of patients enrolled)

